Every 8-K that Immunome, Inc. (IMNM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMNM filings page.
Immunome, Inc. reported second quarter 2026 results and highlighted major oncology pipeline progress. Varegacestat advanced with U.S. FDA acceptance of its New Drug Application for adults with desmoid tumors and a PDUFA target action date of April 28, 2027, following positive Phase 3 RINGSIDE data that showed an 84% reduction in risk of disease progression or death versus placebo and higher objective response rates.
The company dosed first patients in 2026 Phase 1 trials for IM-1617, a solid tumor antibody-drug conjugate, and IM-3050, a FAP-targeted radioligand therapy, while the IM-1021 Phase 1 trial continues with objective responses in B-cell lymphoma. As of June 30, 2026, Immunome held $520.0 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2028. For the quarter, there was no collaboration revenue compared with $4.0 million a year earlier, operating expenses increased, and the company recorded a net loss of $73.1 million.
Immunome, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. As of the April 16, 2026 record date, 113,249,519 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class III directors to serve until the 2029 Annual Meeting: James Boylan, Sandra Swain, M.D., and Philip Wagenheim. For example, Sandra Swain received 92,157,301 votes for and 224,265 votes withheld, with 11,768,578 broker non-votes.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 104,100,900 votes for, 27,134 against, and 22,110 abstentions. An advisory vote approved named executive officer compensation, with 90,908,436 votes for and 1,442,116 against. In a separate advisory vote on frequency, stockholders indicated a preference for annual say-on-pay votes, and the company will hold future advisory compensation votes every year in line with that preference.
Immunome, Inc. reported first quarter 2026 results and highlighted major advances in its oncology pipeline. For the quarter ended March 31, 2026, the company recorded a net loss of $53.8 million, or $0.48 per share, compared with a net loss of $41.6 million a year earlier, as research and development expenses rose to $46.4 million. Cash and cash equivalents were $582.7 million, which the company believes can fund operations into 2028.
Strategically, Immunome submitted a New Drug Application to the U.S. FDA in April 2026 for varegacestat in adults with desmoid tumors, following the Phase 3 RINGSIDE trial. That trial showed an 84% reduction in the risk of disease progression or death versus placebo, with a hazard ratio of 0.16 and objective response rate of 56% vs. 9%. The company also advanced multiple antibody-drug conjugate programs, with IM-1021 in Phase 1, IM-3050 initiating Phase 1, and IM-1617 receiving IND clearance.
Immunome, Inc. reported full-year 2025 results and highlighted major progress across its oncology pipeline. The company posted a net loss of $212.4 million, improving from $293.0 million in 2024, on collaboration revenue of $6.9 million. Research and development expenses were $177.3 million and general and administrative expenses were $43.8 million, both reflecting higher investment and share-based compensation.
Immunome ended 2025 with cash and cash equivalents of $653.5 million, boosted by a December underwritten public offering that raised $460.5 million in gross proceeds. Management expects this cash position to fund operations into 2028.
Clinically, the Phase 3 RINGSIDE trial of varegacestat in desmoid tumors met its primary endpoint with an 84% reduction in risk of progression or death (hazard ratio 0.16, p<0.0001) and a 56% objective response rate versus 9% on placebo. Immunome plans a New Drug Application submission in the second quarter of 2026, while also advancing IM-1021, IM-3050 and multiple early-stage ADC programs toward key 2026 milestones.
Immunome, Inc. is conducting a follow-on public offering of 18,625,000 shares of common stock at $21.50 per share, for expected gross proceeds of approximately $400 million before underwriting discounts, commissions and expenses. All shares are being sold by the company, and the closing is expected on December 18, 2025, subject to customary conditions. The underwriting syndicate is led by Leerink Partners, J.P. Morgan, TD Securities (USA), Goldman Sachs & Co. and Guggenheim Securities, and they have a 30-day option to buy up to an additional 2,793,750 shares at the public offering price, less underwriting discounts and commissions.
Immunome reported positive topline results from its global Phase 3 RINGSIDE trial of varegacestat, an oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.
The study met its primary endpoint of progression-free survival, cutting the risk of disease progression or death by 84% vs placebo (hazard ratio 0.16; 95% CI 0.071–0.375; p<0.0001). Confirmed objective response rate was 56% with varegacestat versus 9% with placebo, and median best tumor volume change was -83% vs +11% with placebo. All key secondary endpoints, including landmark tumor volume reduction and worst pain intensity, showed statistically significant benefits. Varegacestat was generally well tolerated, though diarrhea, fatigue, rash, nausea and cough were common, and about 55.6% of premenopausal women experienced ovarian toxicity. Immunome plans to present additional RINGSIDE data and submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026. The company also highlighted preclinical data suggesting its HC74 TOP1 inhibitor ADC payload may offer advantages over existing TOP1 inhibitor payloads.
Immunome (IMNM) filed an 8-K announcing third-quarter results. The company reported its financial results for the quarter ended September 30, 2025 and provided a business update via a press release furnished as Exhibit 99.1.
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition). The press release is furnished, not filed, which means it is not subject to Section 18 liabilities and is not incorporated into other SEC filings unless expressly referenced. The filing also lists the Inline XBRL cover page as Exhibit 104.